Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial
Howard E Gendelman, Yuning Zhang, Pamela Santamaria, Katherine E Olson, Charles R Schutt, Danish Bhatti, Bhagya Laxmi Dyavar Shetty, Yaman Lu, Katherine A Estes, David G Standaert, Elizabeth Heinrichs-Graham, LuAnn Larson, Jane L Meza, Matthew Follett, Erica Forsberg, Gary Siuzdak, Tony W Wilson, Carolyn Peterson, R Lee Mosley, Howard E Gendelman, Yuning Zhang, Pamela Santamaria, Katherine E Olson, Charles R Schutt, Danish Bhatti, Bhagya Laxmi Dyavar Shetty, Yaman Lu, Katherine A Estes, David G Standaert, Elizabeth Heinrichs-Graham, LuAnn Larson, Jane L Meza, Matthew Follett, Erica Forsberg, Gary Siuzdak, Tony W Wilson, Carolyn Peterson, R Lee Mosley
Abstract
A potential therapeutic role for immune transformation in Parkinson's disease evolves from more than a decade of animal investigations demonstrating regulatory T cell (Treg) nigrostriatal neuroprotection. To bridge these results to human disease, we conducted a randomized, placebo-controlled double-blind phase 1 trial with a well-studied immune modulator, sargramostim (granulocyte-macrophage colony-stimulating factor). We enrolled 17 age-matched non-Parkinsonian subjects as non-treated controls and 20 Parkinson's disease patients. Both Parkinson's disease patients and controls were monitored for 2 months for baseline profiling. Parkinson's disease patients were then randomized into two equal groups to self-administer placebo (saline) or sargramostim subcutaneously at 6 μg/kg/day for 56 days. Adverse events for the sargramostim and placebo groups were 100% (10/10) and 80% (8/10), respectively. These included injection site reactions, increased total white cell counts, and upper extremity bone pain. One urticarial and one vasculitis reaction were found to be drug and benzyl alcohol related, respectively. An additional patient with a history of cerebrovascular disease suffered a stroke on study. Unified Parkinson's disease rating scale, Part III scores in the sargramostim group showed modest improvement after 6 and 8 weeks of treatment when compared with placebo. This paralleled improved magnetoencephalography-recorded cortical motor activities and Treg numbers and function compared with pretreated Parkinson's disease patients and non-Parkinsonian controls. Peripheral Treg transformation was linked to serum tryptophan metabolites, including L-kynurenine, quinolinic acid, and serotonin. These data offer a potential paradigm shift in modulating immune responses for potential therapeutic gain for Parkinson's disease. Confirmation of these early study results requires larger numbers of enrolled patients and further clinical investigation.
Conflict of interest statement
All authors indicate no competing interests.
Figures
References
- Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72:S1–S136. doi: 10.1212/WNL.0b013e3181a1d44c.
- Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2012;2:a009381. doi: 10.1101/cshperspect.a009381.
- Reynolds AD, et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J. Immunol. 2010;184:2261–2271. doi: 10.4049/jimmunol.0901852.
- Shameli A, et al. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology. 2016;221:333–340. doi: 10.1016/j.imbio.2015.10.002.
- Benner EJ, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE. 2008;3:e1376. doi: 10.1371/journal.pone.0001376.
- Hirsch, E. C. et al. Animal models of Parkinson’s disease in rodents induced by toxins: an update. J. Neural. Transm. Suppl.65, 89–100 (2003).
- Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004;22:531–562. doi: 10.1146/annurev.immunol.21.120601.141122.
- Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol. Rev. 2005;204:184–194. doi: 10.1111/j.0105-2896.2005.00250.x.
- Rowin J, et al. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012;46:449–453. doi: 10.1002/mus.23488.
- Smith TJ, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 2006;24:3187–3205. doi: 10.1200/JCO.2006.06.4451.
- Kosloski LM, Kosmacek EA, Olson KE, Mosley RL, Gendelman HE. GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J. Neuroimmunol. 2013;265:1–10. doi: 10.1016/j.jneuroim.2013.10.009.
- Mangano EN, et al. Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson’s disease. Neurobiol. Dis. 2011;43:99–112. doi: 10.1016/j.nbd.2011.02.011.
- Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37:921–943. doi: 10.1007/s40264-014-0226-z.
- Saunders JA, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease. J. Neuroimmune Pharmacol. 2012;7:927–938. doi: 10.1007/s11481-012-9402-z.
- Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn’s disease. N. Engl. J. Med. 2005;352:2193–2201. doi: 10.1056/NEJMoa041109.
- Li S, et al. Predicting network activity from high throughput metabolomics. PLoS Comput. Biol. 2013;9:e1003123. doi: 10.1371/journal.pcbi.1003123.
- Heinrichs-Graham E, et al. Hypersynchrony despite pathologically reduced beta oscillations in patients with Parkinson’s disease: a pharmaco-magnetoencephalography study. J. Neurophysiol. 2014;112:1739–1747. doi: 10.1152/jn.00383.2014.
- Heinrichs-Graham E, et al. Neuromagnetic evidence of abnormal movement-related beta desynchronization in Parkinson’s disease. Cereb. Cortex. 2014;24:2669–2678. doi: 10.1093/cercor/bht121.
- Allen NE, Moloney N, van Vliet V, Canning CG. The rationale for exercise in the management of pain in Parkinson’s disease. J. Parkinsons Dis. 2015;5:229–239. doi: 10.3233/JPD-140508.
- Rana AQ, Kabir A, Jesudasan M, Siddiqui I, Khondker S. Pain in Parkinson’s disease: analysis and literature review. Clin. Neurol. Neurosurg. 2013;115:2313–2317. doi: 10.1016/j.clineuro.2013.08.022.
- Toda K, Harada T. Prevalence, classification, and etiology of pain in Parkinson’s disease: association between Parkinson’s disease and fibromyalgia or chronic widespread pain. Tohoku J. Exp. Med. 2010;222:1–5. doi: 10.1620/tjem.222.1.
- Beiske AG, Loge JH, Ronningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141:173–177. doi: 10.1016/j.pain.2008.12.004.
- Gendelman HE, Mosley RL. A perspective on roles played by innate and adaptive immunity in the pathobiology of neurodegenerative disorders. J. Neuroimmune Pharmacol. 2015;10:645–650. doi: 10.1007/s11481-015-9639-4.
- Lacan G, et al. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. J. Neurosci. Res. 2013;91:1292–1302. doi: 10.1002/jnr.23253.
- Chung ES, et al. Bee venom phospholipase A2, a novel Foxp3+ regulatory T cell inducer, protects dopaminergic neurons by modulating neuroinflammatory responses in a mouse model of Parkinson’s disease. J. Immunol. 2015;195:4853–4860. doi: 10.4049/jimmunol.1500386.
- Henkel JS, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64–79. doi: 10.1002/emmm.201201544.
- Liesz A, et al. Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. J. Neurosci. 2013;33:17350–17362. doi: 10.1523/JNEUROSCI.4901-12.2013.
- Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344:519–523. doi: 10.1126/science.1249547.
- Dansokho C, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139:1237–1251. doi: 10.1093/brain/awv408.
- Ye M, et al. Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease. J. Neuroinflammation. 2016;13:10. doi: 10.1186/s12974-016-0476-z.
- Spitz C, et al. Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential. Cell. Mol. Life Sci. 2016;73:901–922. doi: 10.1007/s00018-015-2080-2.
- Brochard V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009;119:182–192.
- Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 2005;11:493–498. doi: 10.1016/j.parkreldis.2005.07.005.
- Olson KE, Gendelman HE. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Curr. Opin. Pharmacol. 2016;26:87–95. doi: 10.1016/j.coph.2015.10.006.
- Piedavent-Salomon M, et al. Multiple sclerosis associated genetic variants of CD226 impair regulatory T cell function. Brain. 2015;138:3263–3274. doi: 10.1093/brain/awv256.
- Sheng JR, Li LC, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin. Immunol. 2008;128:172–180. doi: 10.1016/j.clim.2008.03.509.
- Wang F, et al. Splenocytes derived from young WT mice prevent AD progression in APPswe/PSENldE9 transgenic mice. Oncotarget. 2015;6:20851–20862. doi: 10.18632/oncotarget.4930.
- Mbongue, J. C. et al. The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. Vaccines3, 703–729 (2015).
- Hill M, et al. IDO expands human CD4+ CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol. 2007;37:3054–3062. doi: 10.1002/eji.200636704.
- Kwidzinski E, Bechmann I. IDO expression in the brain: a double-edged sword. J. Mol. Med. 2007;85:1351–1359. doi: 10.1007/s00109-007-0229-7.
- Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J. 1997;326:351–356. doi: 10.1042/bj3260351.
- Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137–143. doi: 10.1016/j.it.2012.10.001.
- Brodacki B, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic Parkinsonism. Neurosci. Lett. 2008;441:158–162. doi: 10.1016/j.neulet.2008.06.040.
- Goetz CG, et al. Movement disorder society task force report on the hoehn and yahr staging scale: status and recommendations. Mov. Disord. 2004;19:1020–1028. doi: 10.1002/mds.20213.
- Deguchi H, et al. Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. Blood. 2015;126:1595–1600. doi: 10.1182/blood-2015-03-636761.
- Wiesman AI, et al. Quiet connections: reduced fronto-temporal connectivity in nondemented Parkinson’s disease during working memory encoding. Hum. Brain Mapp. 2016;37:3224–3235. doi: 10.1002/hbm.23237.
- Oswal A, et al. Deep brain stimulation modulates synchrony within spatially and spectrally distinct resting state networks in Parkinson’s disease. Brain. 2016;139:1482–1496. doi: 10.1093/brain/aww048.
- van Wijk BC, et al. Subthalamic nucleus phase-amplitude coupling correlates with motor impairment in Parkinson’s disease. Clin. Neurophysiol. 2016;127:2010–2019. doi: 10.1016/j.clinph.2016.01.015.
- te Woerd ES, Oostenveld R, Bloem BR, de Lange FP, Praamstra P. Effects of rhythmic stimulus presentation on oscillatory brain activity: the physiology of cueing in Parkinson’s disease. Neuroimage Clin. 2015;9:300–309. doi: 10.1016/j.nicl.2015.08.018.
- Taulu S, Simola J. Spatiotemporal signal space separation method for rejecting nearby interference in MEG measurements. Phys. Med. Biol. 2006;51:1759–1768. doi: 10.1088/0031-9155/51/7/008.
- Van Veen BD, van Drongelen W, Yuchtman M, Suzuki A. Localization of brain electrical activity via linearly constrained minimum variance spatial filtering. IEEE Trans. Biomed. Eng. 1997;44:867–880. doi: 10.1109/10.623056.
- Hillebrand A, Singh KD, Holliday IE, Furlong PL, Barnes GR. A new approach to neuroimaging with magnetoencephalography. Hum. Brain Mapp. 2005;25:199–211. doi: 10.1002/hbm.20102.
Source: PubMed